Claims for Patent: 8,062,663

Summary for Patent: 8,062,663

Title:	Methods and compostions for enhancing transdermal drug delivery
Abstract:	Methods and compositions for enhancing transdermal delivery of a bioactive agent. The method contains the step of applying to a skin tissue an effective amount of a composition comprising: (a) a drug vehicle; (b) a bioactive agent encapsulated within the drug vehicle; (c) a plurality of proteolytic enzyme molecules conjugated onto the surface of the drug vehicle; and (d) a pharmaceutically acceptable carrier, for a period of time effective to deliver the bioactive agent across the skin tissue at a desired dosage.
Inventor(s):	Wang; Yu-Jing (Taichung, TW), Wang; Yu-Chao (Taipei, TW), Wu; Yi-Ting (Taoyuan, TW), Tai; Lin-Ai (Hsin-Chu, TW), Lo; Leu-Wei (Taipei, TW), Yang; Chung-Shi (Taichung, TW)
Assignee:	National Health Research Instittues (Miaoli County, TW)
Application Number:	12/466,011
Patent Claims:	1. A method for enhancing delivery of a bioactive agent across a skin tissue comprising the step of: applying an effective amount of a composition comprising: a) a liposome; b) a bioactive agent encapsulated within the liposome; c) a plurality of proteolytic enzyme molecules conjugated onto the surface of the liposome; and d) a pharmaceutically acceptable carrier, for a period of time effective to deliver the bioactive agent across the skin tissue at a desired dosage. 2. The method of claim 1, wherein the composition further comprises a nanoparticle enclosed in the liposome, wherein the bioactive agent is encapsulated within the nanoparticle within the liposome. 3. The method of claim 2, wherein the nanoparticle is formed from poly(lactic-co-glycolic acid) (PLGA) or hydro-gel. 4. The method of claim 1, wherein the proteolytic enzyme is papain. 5. The method of claim 4, wherein the concentration of papain is less than 93, or less than 50, 40 or 30 .mu.g/ml. 6. The method of claim 1, wherein the proteolytic enzyme is a selected from the group consisting of papain, pancreatin, ficin, bromelain, elastase, pepsin, hyaluronidase, streptokinase, streptodornase, trypsin, chymotrypsin, .alpha.-chymotrypsin, .alpha.-amylase, deoxyribonuclease, collagenase, sutilain and any combination thereof. 7. The method of claim 1, wherein the bioactive agent comprises two or more than two types of bioactive agents. 8. The method of claim 7, wherein the two or more than two types of bioactive agents comprises at least one type of hydrophilic bioactive agent. 9. The method of claim 1, wherein the bioactive agent is a hormone. 10. A composition for transdermal administration of a bioactive agent comprising: a) a liposome; b) a bioactive agent encapsulated within the liposome; c) a plurality of proteolytic enzyme molecules conjugated onto the surface of the liposome; and d) a pharmaceutically acceptable carrier, wherein the proteolytic enzyme is selected from the group consisting of papain, pancreatin, ficin, bromelain, elastase, pepsin, hyaluronidase, streptokinase, streptodornase, trypsin, chymotrypsin, .alpha.-chymotrypsin, .alpha.-amylase, deoxyribonuclease, collagenase, sutilain and any combination thereof. 11. The composition of claim 10, wherein the enzyme is papain. 12. The composition of claim 11, wherein the concentration of papain is less than 93, or less than 50, 40 or 30 .mu.g/ml. 13. The composition of claim 10, wherein the composition further comprises a nanoparticle enclosed within the liposome, and wherein the bioactive agent is encapsulated within the nanoparticle within the liposome. 14. The composition of claim 13, wherein the nanoparticle is formed from poly(lactic-co-glycolic acid) (PLGA) nanoparticle or hydro-gel. 15. A composition for transdermal administration of a bioactive agent comprising: a) a liposome; b) a bioactive agent encapsulated within the liposome; c) a plurality of papain molecules conjugated onto the surface of the liposome; and d) a pharmaceutically acceptable carrier. 16. The composition of claim 15, wherein the concentration of papain is less than 93, or less than 50, 40 or 30 .mu.g/ml. 17. The composition of claim 15, wherein the composition further comprises a nanoparticle enclosed within the liposome, and wherein the bioactive agent is encapsulated within the nanoparticle within the liposome. 18. The composition of claim 17, wherein the nanoparticle is formed from poly(lactic-co-glycolic acid) (PLGA) nanoparticle or hydro-gel. 19. The method of claim 15, wherein the bioactive agent comprises two or more than two types of bioactive agents.

Details for Patent 8,062,663

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	05/05/2004		2028-05-23
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	12/02/2004		2028-05-23
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	10/26/2004		2028-05-23
Akorn, Inc.	HYDASE	hyaluronidase	Injection	021716	10/25/2005		2028-05-23
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2028-05-23